Mineralys Therapeutics to Participate in Three Upcoming Conferences

Rhea-AI Summary

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) announced senior management's participation in upcoming healthcare conferences in New York, London, and Miami. The company will present and engage in fireside chats, discussing its focus on developing medicines for hypertension, chronic kidney disease, and other aldosterone-driven diseases.

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6^th Annual HealthCONx Conference being held in Miami on November 28-30.

Stifel Healthcare Conference:
Date:	Wednesday, November 15, 2023
Time:	12:40pm EST
Format:	Fireside Chat
Jefferies London Healthcare Conference:
Date:	Thursday, November 16, 2023
Time:	10:30am GMT
Format:	Corporate Presentation
Webcast:	Link
Evercore ISI 6th Annual HealthCONx Conference:
Date:	Wednesday, November 29, 2023
Time:	11:15am EST
Format:	Fireside Chat
Webcast:	Link

A live webcast of the presentation and fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:
Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

What is the purpose of Mineralys Therapeutics, Inc.'s participation in the upcoming conferences?

Mineralys Therapeutics, Inc. aims to present its focus on developing medicines for hypertension, chronic kidney disease, and other aldosterone-driven diseases, and engage in discussions with industry professionals.

When and where will the conferences take place?

The Stifel Healthcare Conference will be held in New York on November 14-15, the Jefferies London Healthcare Conference will take place in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference will be held in Miami on November 28-30.

How can the public access the presentations and fireside chats?

The live webcast of the presentations and fireside chats can be accessed on the Investor Relations section of the Mineralys website at www.mineralystx.com, with replays available for approximately 90 days.